TAp63-Regulated miRNAs Suppress Cutaneous Squamous Cell Carcinoma through Inhibition of a Network of Cell-Cycle Genes

• Published in: Cancer research (Chicago, Ill.) Vol. 80; no. 12; pp. 2484 - 2497
• Main Authors: Davis, Andrew John, Tsinkevich, Maksym, Rodencal, Jason, Abbas, Hussein A, Su, Xiao-Hua, Gi, Young-Jin, Fang, Bin, Rajapakshe, Kimal, Coarfa, Cristian, Gunaratne, Preethi H, Koomen, John M, Tsai, Kenneth Y, Flores, Elsa R
• Format: Journal Article
• Language: English
• Published: United States 15.06.2020
• Subjects: Animals; Aurora Kinase A - genetics; Carcinoma, Squamous Cell - genetics; Cell Proliferation - genetics; Humans; Kinesin; Membrane Proteins; Mice; MicroRNAs - genetics; Protein-Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proteomics; Skin Neoplasms - genetics; Ultraviolet Rays
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.CAN-19-1892

TAp63 is a p53 family member and potent tumor and metastasis suppressor. Here, we show that mice exhibit an increased susceptibility to ultraviolet radiation-induced cutaneous squamous cell carcinoma (cuSCC). A human-to-mouse comparison of cuSCC tumors identified miR-30c-2* and miR-497 as underexpressed in TAp63-deficient cuSCC. Reintroduction of these miRNAs significantly inhibited the growth of cuSCC cell lines and tumors. Proteomic profiling of cells expressing either miRNA showed downregulation of cell-cycle progression and mitosis-associated proteins. A mouse to human and cross-platform comparison of RNA-sequencing and proteomics data identified a 7-gene signature, including , and , which were overexpressed in cuSCC. Knockdown of these factors in cuSCC cell lines suppressed tumor cell proliferation and induced apoptosis. In addition, selective inhibition of AURKA suppressed cuSCC cell proliferation, induced apoptosis, and showed antitumor effects . Finally, treatment with miR-30c-2* or miR-497 miRNA mimics was highly effective in suppressing cuSCC growth . Our data establish TAp63 as an essential regulator of novel miRNAs that can be therapeutically targeted for potent suppression of cuSCC. SIGNIFICANCE: This study provides preclinical evidence for the use of miR-30c-2*/miR-497 delivery and AURKA inhibition in the treatment of cuSCC, which currently has no FDA-approved targeted therapies. .